MAP2K7 and non-small cell lung carcinoma: Current guidelines for BRAFV600-mutant NSCLC recommend BRAF-targeted therapy in the first-line setting, but the optimal course for patients who do not tolerate or progress while on first-line BRAF and MEK inhibitor combinations remains ambiguous21,22.